Currently listed contraindications to the use of metformin - More harmful than beneficial?;Traditionelle metformin-kontraindikationen - Mehr schaden als nutzen?

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 3, 2006, Pages 105-110

  Holstein, Andreas ^a   Egberts, E H ^a  

^a KLINIKUM LIPPE DETMOLD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUFORMIN; METFORMIN; PHENFORMIN; TOLBUTAMIDE;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CREATININE CLEARANCE; DIARRHEA; DRUG CONTRAINDICATION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS;

ACIDOSIS, LACTIC; AGE FACTORS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; METFORMIN; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 32044467375     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924934     Document Type: Review

References (51)

1. Actos 45mg Tabletten (Fachinformation). Takeda Pharma, Januar 2005, 2005
2. Ahmad S, Beckett M. Recovery from pH 6,38: lactic acidosis complicated by hypothermia. Emerg Med J 2002; 19: 169-171
3. Bailey CJ, Turner RC Metformin. N Engl J Med 1996; 334: 574-579
4. British National Formulary No. 49 (March 2005) 6.1.2.2. Metformin Hydrochloride 2005
5. British National Formulary No. 49 (March 2005) 6.1.2.3. Other antidiabetics 2005
6. Brown JB, Pedula K, Barzlay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663
7. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002; 162: 434-437
8. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
9. Conolly V, Kesson CM. Metformin treatment in NIDDM patients with mild renal impairment. Postgrad Med J 1996; 72: 352-354
10. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005; 28: 539-543
11. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in non insulin-dependent diabetes mellitus. J Endocrinol Metabol 1996;81:4059-4067
12. DeFronzo RA, Goodman A Metformin Investigator Group. Efficacy of metformin in patients with non-insulin diabetes mellitus. N Engl J Med 1995;333:541-549
13. Deutsche Diabetes-Gesellschaft. Evidenzbasierte Leitlinie: Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetes und Stoffwechsel 2003; 12: 13-31
14. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ for the Metformin Trial Group. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005; 22: 634-640
15. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-749
16. Ellis AK, Iliescu EA. Metformin-associated lactic acidosis in a low risk patient. Can J Clin Pharmacol 2001; 8: 104-106
17. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001; 18: 483-488
18. Eurich DT, Majumdar SR, McAlister FA, Ross TT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351
19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 328: 1304-1305
20. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992; 152: 2333-2336
21. Glucophage 500mg/-850mg/-1000mg (Packungsbeilage). Darmstadt, Germany, Merck, 2005
22. Gregorio F, Ambrosi F, Filipponi P, Manfrini S, Testa I. Is metformin safe enough for ageing type 2 diabetic patients? Diabetes Metab 1996; 22: 43-50
23. Hermann LS, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. Br J Diabetes Vasc Dis 2004; 4: 401-406
24. Holstein A, Nahrwold D, Hinze S, Egberts E-H. Contraindications to metformin therapy are largely disregarded. Diabet Med 1999; 16: 692-696
25. Horlen C, Malone R, Bryant B et al. Frequency of inappropriate metformin prescriptions. JAMA 2002; 287: 2504-2505
26. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Safety 1999; 20: 489-503
27. Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care 2005; 28: 922-924
28. Kreisberg R, Pennington L, Boshell B. Lactate turnover and gluconeogenesis in obesity: effect of phenformin. Diabetes 1970; 19: 64-69
29. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-241
30. Lalau JD, Lacroix C, Compagnon P et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779-784
31. Lalau JD, Race JM, Brinquin L. Lactic acidosis in metformin therapy. Relationship between plasma metformin concentration and renal function. Diabetes Care 1998; 21: 1366-1367
32. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 30: 461-470
33. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003; 290: 81-85
34. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gabbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338: 256-266
35. Paolisso G, Amato L, Eccellente R et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28: 441-446
36. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002; 13: 428-433
37. Rakovac I, Jeitler K, Gfrerer RJ the FQSD Austria. Patients with Type 2 diabetes treated with metformin: prevalence of contraindications and their correlation with discontinuation. Diabet Med 2005; 22: 662-664
38. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003; 163: 2594-2602
39. Schäfer G. Some new aspects of the interaction of hypoglycaemia-producing biguanides with biological membrane. Biochem Pharmacol 1976; 25: 2075-2076
40. Scheen AJ. Drug interactions of clinical impotance with antihyperglycaemic agents: an update. Drug Safety 2005; 28: 601-631
41. Schure PJ, de Gooijer A, van Zanten AR. Unexpected survival from severe metformin-associated lactic acidosis. Neth J Med 2003; 61: 331-333
42. Searle GL, Siperstein MDX. Lactic acidosis associated with phenformin therapy: Evidence that inhibited lactate oxidation is the causative factor. Diabetes 1970; 24: 64-69
43. Sirtori CR, Pasik C. Re-evaluation of a biguanide metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 187-228
44. Stades AME, Heikens JT, Erkelens DW, Holleman F, Hoekstra BL. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-187
45. Stang MR, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-927
46. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554
47. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20: 925-928
48. UKPDS Group. Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes. United Kingdom Prospective Diabetes Study. Lancet 1998; 352: 854-865
49. University Group Diabetes Program. A study of the effects hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Mortality results. Diabetes 1970; 19: 789-830(Suppl II
50. Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993; 44: 589-591
51. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174